Potential blockbuster submitted by Novo Nordisk for European approval
The EMA can begin reviewing hemophilia treatment concizumab, which used to carry the orphan drug badge until recently, when the company decided not to take advantage of the status.
by christian bundgaard, translated by daniel pedersen
In the near future and if everything goes according to plan, Novo Nordisk will be able to offer patients a new antibody treatment for both hemophilia A and B in Europe.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
.jpg&w=384&q=75)
